Novartis has unveiled Phase III data showing that partnering Kisqali with an endocrine therapy significantly prolonged progression-free survival compared to an endocrine therapy alone in patients with breast cancer.
Novartis’ Rydapt , the first and only targeted therapy approved in Europe for FLT3-mutated acute myeloid leukaemia (AML), has been rejected for NHS use by the National Institute for Health and Care Excellence.
The deadline for completed multiple choice questionnaires (MCQ's - Stage 1 of the competition) and essays (Stage 2, otherwise known as the 'Clinical Challenge') is 31 January and with the festive season approaching, it's sure to come round much faster than you think.
AstraZeneca says top-line results from a post-marketing study show that Tudorza Pressair is effective in reducing chronic obstructive pulmonary disease (COPD) exacerbations in patients with cardiovascular issues.
Merck Sharp & Dohme and Telefonica's Wayra UK have unveiled the next focus of their digital health innovation accelerator programme, calling on tech start-ups to "re-imagine healthcare" with the help of artificial intelligence and machine learning.